Trimethoprim

Introduction Overview

Generic Name

trimethoprim

Brand Name

Primsol, Trimpex, Proloprim

Dosage Form

oral tablet (100 mg)

Drug Class

Urinary anti-infectives

Pharmacokinetics

Absorption:
Trimethoprim exhibits good oral bioavailability with rapid absorption from the gastrointestinal tract. Oral administration leads to peak plasma concentrations generally achieved within 1 to 4 hours. Absorption may be somewhat influenced by concurrent food intake, but this does not significantly impact clinical efficacy. Trimethoprim is well absorbed via the oral route, making it suitable for outpatient therapy of urinary tract infections and other susceptible infections.

Distribution:
After absorption, trimethoprim is widely distributed throughout body tissues and fluids, including the kidneys, bladder, and middle ear, rendering it effective for infections in these sites. It crosses the placental barrier and is found in breast milk, necessitating caution when administered during pregnancy and breastfeeding. Volume of distribution approximates 1.5 to 2 L/kg, indicating extensive tissue penetration. Trimethoprim binds moderately to plasma proteins (approximately 44%), which permits significant free drug availability for antimicrobial activity.

Metabolism:
Trimethoprim undergoes partial hepatic metabolism primarily through demethylation and other oxidative pathways. However, a significant proportion of the drug remains unmetabolized, preserving active antimicrobial activity. The metabolic pathways are relatively efficient but subject to variation in patients with hepatic impairment, potentially altering drug clearance.

Elimination:
The elimination of trimethoprim is predominantly renal, with about 50 to 60% of an administered dose excreted unchanged in the urine. The elimination half-life ranges from 8 to 10 hours in healthy adults but can be prolonged in renal impairment, necessitating dose adjustment in patients with compromised kidney function. Renal excretion involves glomerular filtration and tubular secretion. Trimethoprim’s ability to concentrate in the urinary tract supports its role in treating urinary infections effectively.

Dosage Forms

Available Dosage Forms:
Trimethoprim is commercially available primarily as oral tablets with a standard strength of 100 mg per tablet. Additionally, oral liquid formulations (oral solutions) are marketed under some brand names such as Primsol, although the most common dosage form for monotherapy remains the 100 mg oral tablet.

Dosages for Adults and Adolescents:
The usual adult dosage for uncomplicated urinary tract infections is either 100 mg orally every 12 hours or 200 mg orally once daily. Treatment duration typically spans 10 days for initial episodes. For pediatric patients aged 12 years and older, dosing mirrors that of adults (100 mg every 12 hours or 200 mg once daily). For otitis media in children aged 6 months and older, the recommended dose is 5 mg/kg orally every 12 hours for 10 days with a maximum dose of 200 mg per dose. Trimethoprim is not indicated for prophylactic or prolonged use in otitis media.

Specific Patient Populations:
Trimethoprim is contraindicated in infants younger than 2 months due to safety concerns. For pediatric use in otitis media, the minimum approved age is 6 months. Dose adjustments are necessary in patients with renal impairment because of the drug’s primary renal elimination pathway. Pregnant patients require careful consideration due to trimethoprim's potential to interfere with folic acid metabolism, which is crucial for fetal neural tube development. Caution is also advised during breastfeeding due to possible drug excretion in breast milk and effects on the infant.

Mechanism Of Action

Trimethoprim functions as a bacteriostatic antibacterial agent by selectively inhibiting bacterial dihydrofolate reductase (DHFR), a key enzyme in the folic acid synthesis pathway essential for nucleic acid and protein precursor synthesis. By blocking DHFR, trimethoprim prevents the conversion of dihydrofolic acid to tetrahydrofolic acid, leading to inhibition of bacterial DNA synthesis and cell replication.

At the molecular level, trimethoprim has a high affinity for bacterial DHFR but relatively low affinity for human DHFR, which confers selective toxicity to bacteria while minimizing host cell effects. This selective inhibition disrupts the formation of tetrahydrofolate derivatives required for the synthesis of purines, thymidine, and certain amino acids vital for bacterial proliferation.

Cellular pathways affected include a blockade in the folate metabolic cycle, interfering specifically with DNA replication and cell division in microorganisms. Trimethoprim's mechanism is primarily effective against a broad range of gram-negative and some gram-positive bacteria due to their reliance on folate synthesis.

Clinically, trimethoprim is often used alone or in combination with sulfonamides (e.g., sulfamethoxazole) to produce a synergistic bactericidal effect by blocking sequential steps in the folate pathway. This combination enhances antimicrobial efficacy and reduces the potential for bacterial resistance compared to monotherapy. Numerous clinical studies have demonstrated trimethoprim’s effectiveness in treating urinary tract infections, otitis media, and certain systemic bacterial infections caused by susceptible organisms such as Escherichia coli, Proteus spp., Klebsiella spp., and Staphylococcus saprophyticus.

Comparatively, trimethoprim offers an alternative to other urinary anti-infectives such as nitrofurantoin and fluoroquinolones, with a distinct mechanism that targets folate metabolism rather than DNA gyrase or cell wall synthesis. Research highlights trimethoprim’s favorable pharmacokinetic profile for urinary tract concentration and its safety in oral administration.

Pharmacological Actions

Selective inhibition of bacterial dihydrofolate reductase enzyme, blocking folate synthesis.
Bacteriostatic activity against gram-negative and certain gram-positive bacteria.
Effective penetration and concentration in urinary tract tissues and fluids.
Disruption of bacterial DNA synthesis leading to inhibition of replication and growth.
Synergistic antimicrobial effect when combined with sulfonamides, producing bactericidal outcomes.
Minimal inhibition of human dihydrofolate reductase, contributing to selective toxicity.
Therapeutic activity in urinary tract infections, otitis media, and certain systemic infections.
Partial hepatic metabolism with significant renal excretion of unchanged drug.
Oral bioavailability conducive to outpatient and ambulatory care antibiotic therapy.
Interrupts bacterial folate metabolism, an essential pathway for nucleotide biosynthesis.
Demonstrated efficacy against common urinary pathogens including E. coli and Proteus species.
Utility in pediatric and adult populations above specific age thresholds.
Pharmacokinetic properties allow twice-daily or once-daily oral dosing regimens.
Considerations for use in pregnancy and lactation due to folate metabolism interference.
Low incidence of cross-allergenicity with other antibiotic classes.

Therapeutic Or Clinical Uses

Treatment of uncomplicated urinary tract infections caused by susceptible bacteria.
Management of acute otitis media in pediatric patients 6 months and older.
Therapy for bladder and kidney infections due to bacteria such as Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae.
Alternative monotherapy option in patients allergic to sulfonamides or with sulfonamide intolerance.
Treatment of infections caused by coagulase-negative Staphylococcus species including Staphylococcus saprophyticus.
Use in outpatient settings for initial episodes of urinary tract infections.
Occasional off-label use for certain ear infections caused by susceptible bacterial organisms.
Supportive treatment in specific bacterial infections sensitive to folate synthesis inhibition.
Prevention of bacterial resistance development when used appropriately and for full prescribed duration.
Adjunctive therapy in combination with other antimicrobials for broad-spectrum coverage.
Therapeutic utility limited to bacterial infections; ineffective against viral illnesses such as the flu or common cold.
Use restricted in neonates younger than 2 months and infants younger than 6 months for otitis media.
Considered a first-line or second-line agent based on susceptibility patterns and clinical guidelines.
Employed in cases where other urinary anti-infectives are contraindicated or ineffective.
Intervention to reduce bacterial load quickly in uncomplicated infections with good tolerance.

Side Or Adverse Effects

Common gastrointestinal disturbances including vomiting, diarrhea, and stomach pain.
Hypersensitivity reactions such as rash, itching, and mild skin swelling or tongue swelling.
Serious allergic reactions including urticaria (hives), angioedema, and anaphylaxis in rare cases.
Hematologic effects including anemia particularly in patients with folate deficiency.
Potential for hyperkalemia presenting with weakness, nausea, chest pain, irregular heart rhythms, and paresthesia.
Rare but serious skin reactions requiring immediate medical attention.
Symptoms of drug-induced folate deficiency such as sore, swollen tongue and weakness.
Manifestations of severe bacterial colitis including watery or bloody diarrhea, which can occur even post-therapy.
Easy bruising or bleeding manifestations linked to platelet or coagulation abnormalities.
Neurological symptoms including headache, dizziness, confusion, and in overdose, potential depression or flu-like symptoms.
Incidence of allergic skin rash or mild hypersensitivity reactions in some patients.
Potential interactions causing alterations in blood cell counts or electrolyte imbalances.
Signs of systemic hypersensitivity including fever and generalized weakness.
Isolated reports of elevated liver enzymes or hepatic dysfunction.
Potential for prolonged adverse effects with chronic or overdose scenarios.

Precautions

Avoid use in patients with anemia secondary to folate (folic acid) deficiency due to risk of exacerbation.
Perform renal function assessment prior to and during therapy as dose adjustments may be needed.
Use caution in patients with known liver disease because of partial hepatic metabolism.
Pregnant women should avoid use or be closely monitored due to interference with fetal folic acid metabolism and potential teratogenicity.
Not recommended for infants under 2 months of age and should be used cautiously in children under 6 months for otitis media.
Monitor potassium levels in at-risk patients to prevent life-threatening hyperkalemia.
Educate patients on the importance of completing the full course of therapy to prevent resistance.
Inform patients about potential allergic reactions and instruct them to seek immediate medical care if symptoms develop.
Evaluate for potential drug interactions that may enhance or reduce trimethoprim effects.
Use with caution in patients with pre-existing blood disorders or immunocompromised states.
Consider alternative antibiotics when infection with Moraxella catarrhalis is suspected in otitis media.
Patients should inform healthcare providers of all concomitant medications, including over-the-counter drugs and supplements.
Assess for any history of hypersensitivity to trimethoprim or related compounds prior to initiation.
Avoid prophylactic or prolonged use in otitis media due to limited efficacy and resistance concerns.
Discontinue use and seek medical advice if serious side effects or allergic reactions occur.

Warnings

Contraindicated in patients with anemia caused by folate deficiency due to risk of fatal complications.
Serious hypersensitivity reactions including anaphylaxis require immediate discontinuation and emergency care.
Risk of severe skin reactions and hematological toxicity necessitates close monitoring.
Possibility of Clostridioides difficile-associated diarrhea, which can occur during or months after therapy.
Use during pregnancy, especially in the first trimester, may increase risk of fetal neural tube defects due to folate antagonism.
Avoid use in neonates and young infants due to immature renal function and increased risk of toxicity.
Potential for hyperkalemia, particularly in patients with renal impairment or concomitant medications that raise potassium levels.
Risk of drug accumulation and enhanced adverse effects in patients with renal failure if doses are not adjusted.
Concomitant use with other folate antagonists or drugs affecting hematopoiesis must be carefully reviewed.
Trimethoprim may interfere with certain laboratory tests; medical personnel must be informed when patients are receiving this drug.
Risk of serious infections caused by resistant organisms if therapy is inappropriate or incomplete.
Caution advised when using in patients with pre-existing blood disorders or immunosuppression.
Do not use for viral infections such as influenza or common cold, as it will be ineffective and may increase resistance.
Overdose symptoms can develop insidiously and require prompt medical evaluation and supportive care.
Potential interaction with drugs that cause folate deficiency or affect renal potassium excretion.

Contraindication

Known hypersensitivity to trimethoprim or any component of the formulation.
Anemia caused by folate (folic acid) deficiency is an absolute contraindication.
Infants younger than 2 months due to inadequate safety data and risk of toxicity.
Use for treatment of otitis media in infants younger than 6 months.
Patients with a history of severe hypersensitivity reactions to trimethoprim or related agents.
Patients with megaloblastic anemia attributed to folate deficiency.
Use in patients with pre-existing hyperkalemia without careful monitoring and management.
Concurrent use with drugs that strongly antagonize folate metabolism without proper supplementation.
Severe hepatic impairment where drug metabolism is significantly impaired.
Pregnant women in the first trimester unless benefits outweigh the risks and after thorough counseling.

Drug Interactions

Increased risk of hyperkalemia when used with potassium-sparing diuretics, ACE inhibitors, ARBs, or potassium supplements.
Additive bone marrow suppression when combined with other folate antagonists or myelosuppressive agents.
Potential enhancement of warfarin anticoagulant effect leading to increased bleeding risk.
Interactions with phenytoin potentially altering trimethoprim or phenytoin levels.
May potentiate the effects of oral hypoglycemics, increasing risk of hypoglycemia.
Concurrent use with methotrexate may increase methotrexate toxicity due to folate antagonism.
Trimethoprim may affect lab tests including methotrexate levels and folate assays.
Use with drugs that cause hyperkalemia (e.g., heparin) requires caution and monitoring.
Possibility of interaction with cyclosporine increasing nephrotoxicity risk.
May increase plasma levels of digoxin by influencing renal tubular secretion.
Avoid combination with sulfonamides without close supervision due to enhanced adverse effect profiles.
Drugs that induce hepatic enzymes (e.g., rifampin) may decrease trimethoprim plasma levels.
Co-administration with other antibiotics may modify antimicrobial spectrum and resistance patterns.
Interaction with certain diuretics (e.g., thiazides) can increase risk of blood dyscrasias.
Potential for reduced efficacy when administered with drugs affecting renal clearance.

Preparations Of The Drug

Oral tablet: 100 mg strength, used primarily for urinary tract infections and other indications.
Oral solution (Primsol) for patients requiring liquid formulations, with exact concentration adjusted per brand.
Available under brand names such as Primsol, Trimpex, and Proloprim, which may vary by formulation and regional availability.
Prescribed with dosing regimens tailored to indication, patient age, and renal function status.
Formulations designed for oral administration with sufficient bioavailability and tissue penetration.
Packaged with dosing instructions and measuring devices for oral solutions to ensure accurate administration.
NOT available as intravenous formulations; oral administration is the standard route.
Supplied in blister packs or bottles depending on manufacturer and dispensing requirements.
Stability ensured at room temperature with protection from moisture, heat, and light.
Manufactured in compliance with pharmaceutical standards ensuring consistency of dosage and purity.
Available generically and through branded formulations facilitating access and cost considerations.
Monotherapy dosage forms distinct from fixed-combination products containing sulfamethoxazole.
Counseled with clear labeling to avoid confusion with combination drugs such as Bactrim.
Supplementary materials such as medication guides and professional monographs accompany commercial preparations.
Patient resources and support materials provided alongside commercial drug products to enhance adherence.